Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

Hosseini, Seyed Samad; Khalili, Saeed; Baradaran, Behzad; Bidar, Negar; Shahbazi, Mohammad‐Ali; Mosafer, Jafar; Hashemzaei, Mahmoud; Mokhtarzadeh, Ahad; Hamblin, Michael R.

doi:10.1016/j.ijbiomac.2020.11.058

Cited by 54 publications

(29 citation statements)

References 154 publications

(137 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Now, the three most commonly used methods to manufacture bispecific antibodies are chemical conjugation, quadroma, and genetic/protein engineering [ 20 ]. Over the past decades, the tremendous advances in gene engineering and pharmaceutical techniques have led to an development of BsAbs in varied forms [ 21 ]. According to the existence of an Fc region, BsAbs generally can be classified into two major classes: IgG-like molecules (with an Fc domain) and fragment-based molecules (without an Fc domain) (Fig.…”

Section: The Formats Of Bsabsmentioning

confidence: 99%

Recent advances and challenges of bispecific antibodies in solid tumors

Zhu

et al. 2021

Exp Hematol Oncol

View full text Add to dashboard Cite

Cancer immunotherapy has made remarkable progress in the past decade. Bispecific antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody-target cancer immunotherapy, which overwhelmingly focus on T cell recruitment and dual receptors blockade. So far, BsAb drugs have been proved clinically effective and approved for the treatment of hematologic malignancies, but no BsAb have been approved in solid tumors. Numerous designed BsAb drugs for solid tumors are now undergoing evaluation in clinical trials. In this review, we will introduce the formats of bispecific antibodies, and then update the latest preclinical studies and clinical trials in solid tumors of BsAbs targeting EpCAM, CEA, PMSA, ErbB family, and so on. Finally, we discuss the BsAb-related adverse effects and the alternative strategy for future study.

show abstract

Section: The Formats Of Bsabsmentioning

confidence: 99%

Recent advances and challenges of bispecific antibodies in solid tumors

Zhu

et al. 2021

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…Unlike monoclonal antibodies, BsAbs are prepared mainly by recombinant DNA technology and can specifically bind two antigens or epitopes simultaneously (43). BsAb can directly enhance the activity of immune cells against tumors and can also target immune checkpoints and tumor-associated antigens (TAAs) to reverse immunosuppression in the tumor environment.…”

Section: Bispecific Antibody (Bsab) Therapymentioning

confidence: 99%

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Liu

Liang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional therapeutic options that will help only a limited percentage of HCC patients. Cancer immunotherapy has achieved dramatic advances in recent years and provides new opportunities to treat HCC. However, HCC has various etiologies and can evade the immune system through multiple mechanisms. With the rapid development of genetic engineering and synthetic biology, a variety of novel immunotherapies have been employed to treat advanced HCC, including immune checkpoint inhibitors, adoptive cell therapy, engineered cytokines, and therapeutic cancer vaccines. In this review, we summarize the current landscape and research progress of different immunotherapy strategies in the treatment of HCC. The challenges and opportunities of this research field are also discussed.

show abstract

“…In addition to the ones mentioned above, bispecific antibodies that recognize two antigens in a single antibody format are currently being commercialized [132][133][134]. Phage display technology is also used as an essential technology for the development of bispecific antibodies [135][136][137].…”

Section: Conclusion and Prospectsmentioning

confidence: 99%

Phage Display Technology as a Powerful Platform for Antibody Drug Discovery

Nagano

Tsutsumi

2021

Viruses

View full text Add to dashboard Cite

Antibody drugs with a high affinity and specificity are effective and safe for intractable diseases, such as cancers and autoimmune diseases. Furthermore, they have played a central role in drug discovery, currently accounting for eight of the top 20 pharmaceutical products worldwide by sales. Forty years ago, clinical trials on antibody drugs that were thought to be a magic bullet failed, partly due to the immunogenicity of monoclonal antibodies produced in mice. The recent breakthrough in antibody drugs is largely because of the contribution of phage display technology. Here, we reviewed the importance of phage display technology as a powerful platform for antibody drug discovery from various perspectives, such as the development of human monoclonal antibodies, affinity enhancement of monoclonal antibodies, and the identification of therapeutic targets for antibody drugs.

show abstract

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

Cited by 54 publications

References 154 publications

Recent advances and challenges of bispecific antibodies in solid tumors

Recent advances and challenges of bispecific antibodies in solid tumors

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Phage Display Technology as a Powerful Platform for Antibody Drug Discovery

Contact Info

Product

Resources

About